Article Text


422 Surfactant Implementation in Treatment of Respiratory Distress Syndrome - Our Experiences
  1. M Rascanin
  1. Neonatology, GAK ‘Narodni Front’, Belgrade, Serbia, Ruzica Djordjevic, OGC “Narodni front”, Belgrade, Serbia


Introduction Surfactant is mix of lypo-proteins and it synthesizes in the lungs of the fetus. It lines the walls of the alveoli preventing their collapse and prevents athelectasis. The most important indication for use of surfactant is Respiratory Distress Syndrome (RDS) of the preterm infants.

Goal The goal of our paper is to represent our experience in application of surfactant immediately after birth in the prophylaxis of RDS in premature babies.

Method Retrospective analysis of neonatal morbidity of 92 infants during period 2010–2011, to whom prophylactic surfactant administered in our Neonatal Department. We assessed the b vitality at birth, body weight of newborns, gestational age and gender.

Results Analysis of gestational maturity was noted that the 4, 34% of infants had a gestational age of less than 25 weeks of gestation, 45, 65% from 25, 1 to 28 w., 21.19% from 28.1 to 30 and 22.82% ≥30.1w. The average gestational age was 28.3±1.8 weeks. The average Apgar score in the fifth minute was 5.27±1.30. The average body weight was 1086.85 g±253, 47g. 48.92% were male and 51.08% was female. After surfactant therapy, they were transported to the tertiary level institutions in good general condition.

Conclusion Surfactant needs to be applied as early as possible and not allow the infant exhausted. Presence team of neonatologists and pediatric nurses will increase the percentage of infants who have the ability to lower the gestational maturity to be able to live.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.